Welcome to the sixth issue of Life Sciences Spotlight. In this issue, we explore a variety of topics and recent developments that are relevant to businesses operating in the life sciences sector in the Asia Pacific region and globally.

Highlights in this issue:

Trends and developments in cyber security and data protection – Why pharma and life sciences companies should take action

The Myriad of problems and opportunities continues – An update on the patentability of naturally occurring products in Australia and the US

IMED: Telemedicine and the law

Major trends give rise to competition concerns in the Australian life sciences sector

Getting tough on corruption - Why businesses should take a closer look at their activities in Thailand

International mobility and the need for upfront planning – A New Zealand perspective

It's obvious – The Australian High Court rules on AstraZeneca’s Crestor® patent

下载

本期通讯

Pharmaceutical and life sciences companies are increasingly
the target of cyber-attacks and cyber-espionage. It is perhaps the case that these organisations have seen themselves as holding
relative limited amounts of personal information compared
to banks, insurers, retailers, telecommunications service
providers and utilities, and therefore considered that they
face a lower risk of suffering 'privacy' and 'data protection' breaches.

In this edition of Life Sciences Spotlight, members in the DLA Piper Life Sciences team will assist in unravelling the
legal aspects of a real-world Life Sciences dilemma. In this issue, DLA Piper’s IP specialist, Ian Jebbitt and patent
specialist, Bing Li discuss implementing intellectual property enforcement strategies in China as part of
a worldwide strategy to prevent counterfeit pharmaceuticals from entering global markets.